Showing results (641-650 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|November 16, 2021
Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese SubjectsXin Li, Yuan Li, Bing Xu, et al.
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control ParticipantsRidhi Parasrampuria, Susan L Ford, Yu Lou, et al.
Clinical Pharmacology in Drug Development|February 2, 2021
Pharmacokinetics and Safety of Dapoxetine Hydrochloride in Healthy Chinese Men: Impact of Dose and High-Fat MealJingyan Liu, Zhihui Li, Keyu Yan, et al.
Clinical Pharmacology in Drug Development|January 19, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy ParticipantsRoger L Whiting, Borje Darpo, Chunlin Chen, et al.
Clinical Pharmacology in Drug Development|January 27, 2021
Characterization of the Abuse Potential in Adult Smokers of a Novel Oral Tobacco Product Relative to Combustible Cigarettes and Nicotine Polacrilex GumJianmin Liu, Jingzhu Wang, Andrea Vansickel, et al.
Clinical Pharmacology in Drug Development|January 29, 2021
A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative ColitisKenichi Furihata, Yoh Ishiguro, Naoki Yoshimura, et al.
Clinical Pharmacology in Drug Development|January 6, 2022
Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 StudyKenichi Furihata, Izumi Hamada, Takuro Niwa, et al.
Clinical Pharmacology in Drug Development|January 6, 2022
Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 InhibitorChunlin Chen, Liming Zhang, Cristina Almansa, et al.
Clinical Pharmacology in Drug Development|January 12, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 TrialSanjeev Forsyth, Patricia Schroeder, James Geib, et al.
Clinical Pharmacology in Drug Development|January 8, 2022
Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese AdultsTommy Cheung, Fang Sun, June Zhao, et al.
Pageof 136